Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220
Epidemiology and natural history of multiple sclerosis: new insights
Kantarci, O., & Wingerchuk, D. (2006) · Current Opinion in Neurology · doi:10.1097/01.wco.0000227033.47458.82 · Cited by 156
Research works printed but not linked: 24
- Frohman EM. Multiple sclerosis. Med Clin North Am. 2003;87:867–868ix. · DOI
- Goodin DS, Frohman EM, Garmany GP, Jr., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169–178. · DOI · Paper page
- Lubin F, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61:1528–1532. · DOI · Paper page
- Mohr DC, Goodkin DE, Masuoka L, et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Mult Scler. 1999;5:192–197. · DOI
- Ross AP. Tolerability, adherence, and patient outcomes. Neurology. 2008;71:S21–S23. · doi:10.1212/wnl.0b013e31818f3dcb
- Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci. 2003;24:361–364. · doi:10.1007/s10072-003-0190-3
- Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1–9. · DOI · Paper page
- Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61:551–554. · DOI · Paper page
- Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther. 2009;31:1142–1157. · DOI
- Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs. 2003;63:1525–1533. · DOI
- Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–574. · DOI · Paper page
- Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients. Adv Ther. 2008;25:658–673. · DOI
- Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson KP. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Adv Ther. 2009;26:552–562. · doi:10.1007/s12325-009-0028-3
- Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8:469–476. · doi:10.18553/jmcp.2002.8.6.469
- Ollendorf DA, Castelli-Haley J, Oleen-Burkey M. Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis. J Neurosci Nurs. 2008;40:281–290. · doi:10.1097/01376517-200810000-00006
- Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30:89–100. · DOI · Paper page
- Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care. 1998;36:1138–1161. · DOI · Paper page
- Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008;255(Suppl. 6):87–92. · DOI
- Ginsburg PB, Strunk BC, Banker MI, Cookson JP. Tracking health care costs: continued stability but at high rates in 2005. Health Aff (Millwood). 2006;25:w486–w495. · doi:10.1377/hlthaff.25.w486
- Brandes DW, Callender T, Lathi E, O’Leary S. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin. 2009;25:77–92. · DOI
- Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10:225.
- Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256:568–576. · DOI · Paper page
- Tan H, Yu J, Tabby D, Singer J. Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study. Mult Scler. 2009;16:956–963. · DOI
- Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22–33.
Cited by
Economic impact of medication non-adherence by disease groups: a systematic review
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016982 · Cited by 900
Metadata
- Authors
- Tan, H., Cai, Q., Agarwal, S., Stephenson, J. J., & Kamat, S.
- Venue
- Advances in Therapy
- Published
- 2010-12-06
- Volume
- 28
- Issue
- 1
- Pages
- 51-61
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W2061166054
- Cited by
- 222
- References
- 3
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. https://app.cochat.ai/papers/10.1007/s12325-010-0093-7
- The paper
- Tan, H., Cai, Q., Agarwal, S., Stephenson, J. J., & Kamat, S. (2011). Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Advances in Therapy. https://doi.org/10.1007/s12325-010-0093-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.